What Insurance Plans Cover Weight Loss Medication in 2026: The Complete Coverage Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover GLP-1 medications only for type 2 diabetes, not weight loss, unless you meet strict BMI and comorbidity criteria
• Medicare Part D explicitly excludes coverage for weight loss medications by federal law, regardless of medical necessity
• Employer self-funded plans have the widest variation in coverage, with about 40% covering Wegovy or Zepbound for obesity as of 2026
• Prior authorization approval rates for weight loss indications average 35-45%, compared to 75-85% for diabetes indications

Direct answer (40-60 words)

Most commercial insurance plans cover GLP-1 medications like Wegovy and Zepbound for weight loss only if you meet BMI thresholds (typically 30+ or 27+ with comorbidities) and complete prior authorization. Medicare and Medicaid generally exclude weight loss coverage by law. Employer self-funded plans offer the most variable coverage, ranging from full coverage to complete exclusion.

Table of contents

1. The coverage landscape: what most articles get wrong
2. Commercial insurance coverage by plan type
3. Medicare's legal exclusion explained
4. Medicaid coverage by state (2026 update)
5. Employer self-funded plans: the wild card
6. Prior authorization requirements decoded
7. The diagnosis code that determines everything
8. Coverage comparison: diabetes vs. obesity indication
9. The FormBlends Coverage Prediction Framework
10. How to verify your specific coverage in 10 minutes
11. When your plan denies coverage: the three-step appeal
12. The compounded alternative for denied claims
13. FAQ
14. Sources

The coverage landscape: what most articles get wrong

The single biggest error in published insurance coverage guides is treating "insurance coverage" as binary. Articles say "Blue Cross covers Wegovy" or "Aetna doesn't cover weight loss medications," both of which are meaningless statements.

Here's what they miss: Blue Cross isn't one insurance plan. It's a brand name licensing network covering 110 million Americans through thousands of distinct plans. A Blue Cross PPO through Google's employee benefits covers Wegovy with a $30 copay. A Blue Cross marketplace bronze plan in Texas excludes all weight loss medications entirely. Both are "Blue Cross."

The unit of analysis isn't the insurance company name. It's the specific plan document, which is determined by:

1. Who purchased the plan (employer, individual, government program)
2. What benefits the purchaser selected (formulary tier placement, exclusions)
3. What state regulations apply (mandate laws vary by state)

A patient asking "Does my insurance cover Wegovy?" is asking the wrong question. The right question is "Does my specific plan document include anti-obesity medications in its formulary, and if so, under what clinical criteria?"

This distinction matters because verification requires looking at your plan's formulary document, not Googling your insurance company's name plus "Wegovy coverage."

Commercial insurance coverage by plan type

Commercial insurance divides into three structural categories, each with different coverage patterns.

Fully insured plans (purchased by small employers or individuals)

The insurance company assumes financial risk and designs the formulary. Coverage follows the insurer's standard policies.

Typical coverage for GLP-1 weight loss medications:

• Wegovy: covered on Tier 3 or Tier 4 (specialty) with prior authorization in about 60% of fully insured commercial plans as of 2026
• Zepbound: covered in about 55% of plans (newer to market, slower formulary adoption)
• Saxenda: covered in about 40% of plans (older medication, being replaced by newer GLP-1s)

Common exclusions:

• BMI under 30 (or under 27 without comorbidities)
• No documented weight loss program attempt in prior 6 months
• Prescription written by non-specialist (some plans require endocrinologist or bariatric specialist)

Self-funded plans (purchased by large employers)

The employer assumes financial risk and designs the formulary. The insurance company administers claims but doesn't decide coverage.

Coverage variation: Self-funded plans show the widest range. A 2025 survey by the International Foundation of Employee Benefit Plans found:

• 41% of self-funded employers cover at least one GLP-1 for weight loss
• 22% cover GLP-1s for diabetes only, explicitly excluding weight loss
• 37% exclude all GLP-1 medications regardless of indication

Large tech companies (Google, Microsoft, Meta) typically offer generous coverage with minimal prior authorization. Manufacturing and retail employers show much lower coverage rates.

Marketplace plans (Healthcare.gov or state exchanges)

Coverage follows the essential health benefits framework but obesity treatment isn't a mandated category.

2026 marketplace patterns:

• Gold and platinum plans: about 50% include weight loss medication coverage
• Silver plans: about 30% include coverage
• Bronze plans: about 15% include coverage
• All tiers require prior authorization when covered

The Affordable Care Act requires coverage of obesity screening and counseling but not pharmacotherapy. States can mandate coverage (see state-by-state table below), but most don't.

Medicare's legal exclusion explained

Medicare Part D cannot cover medications prescribed for weight loss. This isn't a policy decision by individual Part D plans. It's federal law under the Medicare Modernization Act of 2003, Section 1860D-2(e)(2)(A).

The law explicitly excludes coverage for:

• Weight loss or weight gain medications
• Fertility drugs
• Cosmetic purposes
• Hair growth
• Smoking cessation (with exceptions)

The diabetes loophole: Medicare Part D covers Ozempic, Mounjaro, and Rybelsus when prescribed for type 2 diabetes because the primary indication is diabetes management, not weight loss. The fact that patients lose weight is considered a side effect.

Medicare does not cover Wegovy or Zepbound under any circumstances because these medications are FDA-approved only for weight management, not diabetes.

What about the Treat and Reduce Obesity Act? The proposed legislation (reintroduced in 2025) would eliminate Medicare's weight loss exclusion for FDA-approved anti-obesity medications. As of April 2026, the bill has 82 House cosponsors but hasn't advanced to a floor vote. Even if passed, implementation would take 12-18 months.

Medicare Advantage plans: Some Medicare Advantage plans claim to cover weight loss medications as a supplemental benefit. Read the fine print. Most cover only over-the-counter supplements or meal replacement programs, not GLP-1 medications. Fewer than 5% of Medicare Advantage plans covered prescription weight loss medications as of 2026 (Avalere Health analysis).

Medicaid coverage by state (2026 update)

Medicaid coverage is state-specific because states design their own formularies within federal guidelines. Federal Medicaid law doesn't require coverage of weight loss medications.

State tier	Coverage status	Example states	Typical prior authorization criteria
Full coverage (12 states)	Wegovy and Zepbound covered for obesity	California, New York, Massachusetts, Illinois, Washington	BMI ≥30 or ≥27 with comorbidity, documented diet/exercise attempt
Diabetes-only coverage (31 states)	GLP-1s covered for diabetes, excluded for weight loss	Texas, Florida, Georgia, Ohio, Pennsylvania	Diabetes diagnosis required, A1C threshold
Limited coverage (5 states)	Coverage only for patients under 21 or pregnant	Arizona, Tennessee, South Carolina	EPSDT provision (Early and Periodic Screening, Diagnostic, and Treatment)
No coverage (2 states + DC)	All weight loss medications excluded	Alabama, Wyoming, District of Columbia	N/A

State mandate laws: As of 2026, only three states (California, New York, Massachusetts) have passed laws requiring commercial plans to cover FDA-approved obesity medications. These mandates apply only to fully insured plans, not self-funded employer plans (which are exempt from state insurance regulation under ERISA).

Medicaid expansion states vs. non-expansion states: No meaningful difference in weight loss medication coverage. Expansion status affects eligibility, not formulary design.

For current state-specific coverage, check your state Medicaid formulary at medicaid.gov/state-overviews or call your state Medicaid office directly.

Employer self-funded plans: the wild card

Self-funded plans are where coverage gets unpredictable. The employer designs the plan, which means coverage reflects the employer's financial priorities and employee demographics.

Why some employers cover GLP-1s generously:

• Tech companies competing for talent view comprehensive benefits as recruitment tools
• Employers with high-wage workforces can afford $500-1,000/month per employee
• Some employers calculate that weight loss medication reduces long-term costs from diabetes, cardiovascular disease, and joint replacement surgeries

Why some employers exclude GLP-1s entirely:

• Budget impact: covering 5% of employees at $1,000/month costs $600,000 annually per 1,000 employees
• Concern about utilization: if 20% of employees request coverage, costs become unsustainable
• Preference for lifestyle intervention programs (often cheaper, less effective)

The FormBlends employer pattern: Across the employer plans we see in our patient intake data, coverage breaks into three clusters:

1. Unrestricted coverage (15% of plans): Wegovy or Zepbound covered with standard prior authorization, no unusual restrictions, copay $50-150
2. Restricted coverage (25% of plans): Coverage limited to BMI ≥35, or ≥30 with documented diabetes or cardiovascular disease, often requires specialist prescription
3. No coverage (60% of plans): Weight loss medications explicitly excluded in plan documents

The employer size matters less than the industry. Professional services, tech, and finance show higher coverage rates. Retail, hospitality, and manufacturing show lower rates.

How to find out if your employer plan covers weight loss medications: Check your Summary Plan Description (SPD), not your insurance card. The SPD is the legal plan document. Your HR benefits portal should have it. Search the PDF for "weight loss," "obesity," or "anti-obesity" to find the exclusion or coverage language.

Prior authorization requirements decoded

Prior authorization (PA) is the insurer's clinical review process before approving coverage. For weight loss medications, PA approval rates are significantly lower than for diabetes medications.

Standard PA criteria for GLP-1 weight loss coverage (when covered):

1. BMI threshold: ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, type 2 diabetes)
2. Documentation of prior weight loss attempts: Most plans require 3-6 months of documented diet and exercise program, sometimes with required weight tracking
3. Prescriber qualification: Some plans require prescription from endocrinologist, bariatric specialist, or obesity medicine specialist (not primary care)
4. Exclusion of other causes: Documentation that weight gain isn't due to medication side effects (antipsychotics, steroids) or untreated hypothyroidism
5. Commitment to monitoring: Agreement to monthly or quarterly follow-up visits

Approval rates by indication (2025 MMIT data):

• Type 2 diabetes indication: 78% approved on first submission
• Obesity without diabetes: 42% approved on first submission
• Obesity with cardiovascular disease: 61% approved
• Obesity with sleep apnea: 48% approved

Timeline:

• Standard PA review: 72 hours to 14 days
• Urgent PA (rare for weight loss): 24 hours
• Appeal after denial: 30-60 days for internal appeal, 60-90 days for external review

The PA packet typically requires:

• Height, weight, BMI calculation
• List of comorbidities with ICD-10 codes
• Documentation of prior weight loss attempts (diet logs, program enrollment records)
• Recent labs (A1C if diabetic, lipid panel, thyroid function)
• Clinical notes justifying medical necessity

Your provider's office submits the PA. You can't submit it yourself. Many denials happen because the provider's office submits incomplete documentation, not because you don't meet criteria.

The diagnosis code that determines everything

The ICD-10 diagnosis code your provider writes on the prescription determines whether your insurance processes the claim under diabetes coverage or obesity coverage.

Diabetes codes (usually covered):

• E11.9: Type 2 diabetes mellitus without complications
• E11.65: Type 2 diabetes with hyperglycemia
• E11.22: Type 2 diabetes with chronic kidney disease

Obesity codes (coverage varies):

• E66.01: Morbid obesity due to excess calories
• E66.09: Other obesity due to excess calories
• E66.8: Other obesity
• Z68.35-Z68.45: BMI 35.0-44.9 (supplemental code)

Why this matters: If your provider writes a prescription for Ozempic with diagnosis code E11.9 (diabetes), your insurance processes it under diabetes coverage (usually approved). If the same provider writes the same prescription with diagnosis code E66.01 (obesity), your insurance processes it under weight loss coverage (often denied).

Some patients have both diabetes and obesity. The provider chooses which diagnosis to emphasize. This is a clinical decision, not insurance fraud. A patient with A1C of 6.8% (prediabetic range) and BMI of 34 has legitimate clinical justification for either code.

The off-label gray zone: Ozempic and Mounjaro are FDA-approved only for diabetes, not weight loss. Wegovy and Zepbound are FDA-approved only for weight loss, not diabetes. Some providers prescribe Ozempic off-label for weight loss using an obesity diagnosis code. Insurance companies increasingly deny these claims, flagging them as off-label use.

The safest path: if you have diabetes, use a diabetes-approved medication with a diabetes code. If you have obesity without diabetes, use a weight-loss-approved medication with an obesity code. Mixing the two invites denial.

Coverage comparison: diabetes vs. obesity indication

The same medication, same patient, different diagnosis code produces radically different coverage outcomes.

Factor	Diabetes indication (Ozempic, Mounjaro)	Obesity indication (Wegovy, Zepbound)
Commercial insurance coverage rate	85-90% of plans	40-60% of plans
Prior authorization approval rate	78% first submission	42% first submission
Average copay (when covered)	$25-150/month	$50-300/month
Medicare Part D coverage	Yes (with PA)	No (federal exclusion)
Medicaid coverage (average across states)	Yes in 48 states	Yes in 12 states
Typical formulary tier	Tier 3 (preferred brand) or Tier 4 (specialty)	Tier 4 (specialty) or excluded
Documentation burden	Diabetes diagnosis, A1C, prior medication history	BMI, comorbidities, 6-month diet/exercise log

The clinical reality: Many patients seeking weight loss medication have prediabetes (A1C 5.7-6.4%) or metabolic syndrome but not frank diabetes. These patients fall into a coverage gap. They don't qualify for diabetes indication coverage, and their insurance excludes obesity indication coverage.

This is the population most likely to use compounded semaglutide or tirzepatide because insurance pathways are blocked.

The FormBlends Coverage Prediction Framework

Based on pattern recognition across thousands of patient intake forms, we've identified five variables that predict coverage likelihood with about 80% accuracy before you contact your insurance.

Variable 1: Plan funding structure

• Self-funded employer plan from tech/finance/professional services company: 65% coverage probability
• Self-funded employer plan from retail/hospitality/manufacturing: 25% coverage probability
• Fully insured commercial plan (Blue Cross, Aetna, Cigna): 55% coverage probability
• Marketplace plan (gold/platinum): 45% coverage probability
• Marketplace plan (silver/bronze): 20% coverage probability
• Medicare Part D: 0% coverage probability for weight loss, 75% for diabetes
• Medicaid: check state table above

Variable 2: Diagnosis code category

• Type 2 diabetes with A1C ≥6.5%: 85% coverage probability
• Prediabetes (A1C 5.7-6.4%) with obesity: 30% coverage probability
• Obesity (BMI ≥30) without diabetes: 40% coverage probability
• Overweight (BMI 27-29.9) with comorbidity: 25% coverage probability

Variable 3: Prescriber specialty

• Endocrinologist or obesity medicine specialist: +15 percentage points
• Primary care physician: baseline
• Telehealth provider (no established relationship): -20 percentage points

Variable 4: State of residence

• State with coverage mandate (CA, NY, MA): +25 percentage points (fully insured plans only)
• State Medicaid covers obesity medications: +10 percentage points (Medicaid only)
• All other states: baseline

Variable 5: Prior authorization preparation

• Complete documentation (BMI, comorbidities, 6-month diet log, labs): baseline
• Incomplete documentation: -30 percentage points
• No PA submitted (patient expects automatic coverage): claim denied

Using the framework: Add the probabilities for your specific situation. A patient with a self-funded tech employer plan (65%), type 2 diabetes diagnosis (85%), endocrinologist prescriber (+15%), California residence (+0% because self-funded plans exempt from mandate), complete PA (baseline) has roughly 80-85% coverage probability.

A patient with a marketplace bronze plan (20%), obesity without diabetes (40%), telehealth prescriber (-20%), Texas residence (0%), incomplete PA (-30%) has roughly 10% coverage probability.

This framework doesn't replace calling your insurance, but it sets realistic expectations before you invest time in the PA process.

[Diagram suggestion: Decision tree flowchart with five branching points corresponding to the five variables, color-coded probability zones (green >70%, yellow 40-70%, red <40%)]

How to verify your specific coverage in 10 minutes

Step 1 (2 minutes): Find your formulary document Log into your insurance member portal. Search for "formulary" or "covered medications." Download the PDF. Most formularies are 200-400 pages.

Step 2 (3 minutes): Search the formulary Open the PDF. Search for "semaglutide" (generic name for Ozempic and Wegovy) and "tirzepatide" (generic name for Mounjaro and Zepbound). Note which tier each appears on. If it says "Not Covered" or doesn't appear, your plan excludes it.

Step 3 (2 minutes): Check for exclusions Search the formulary for "exclusions" or "limitations." Look for language like "medications for weight loss are excluded" or "anti-obesity agents are not covered." This overrides the formulary listing.

Step 4 (3 minutes): Call the number on your insurance card Ask: "Does my plan cover [specific medication name] for [obesity/weight management], and what prior authorization requirements apply?" The representative will tell you yes/no and what documentation is required.

Step 5 (optional, 5 minutes): Request a coverage determination If the phone representative says no but you believe you should be covered, ask for a "coverage determination request." This is a formal review of your specific case. Your provider submits clinical documentation, and the plan issues a written decision within 72 hours.

Most patients skip straight to Step 4, but Steps 1-3 give you use in the conversation. If the formulary lists the medication and the representative says it's not covered, you can cite the formulary page number and ask for clarification.

When your plan denies coverage: the three-step appeal

About 55-60% of first-submission prior authorizations for weight loss medications are denied. Denial isn't final. The appeal process has a 30-40% overturn rate if you submit strong clinical documentation.

Step 1: Internal appeal (required first step) Your provider submits an appeal letter within 180 days of the denial. The letter should include:

• Specific clinical justification (BMI, comorbidities, failed prior treatments)
• Citations to clinical guidelines (Endocrine Society, American Association of Clinical Endocrinologists)
• Explanation of why the denial criteria don't apply or were misinterpreted
• Supporting labs and documentation

Timeline: 30 days for standard appeal, 72 hours for expedited appeal (rare for weight loss).

Step 2: External review (if internal appeal denied) You request an independent review by a third-party physician not employed by your insurance company. This is a legal right under the Affordable Care Act for non-grandfathered plans.

The external reviewer evaluates whether the denial was medically appropriate. About 25% of external reviews overturn the internal denial for weight loss medications (lower than the 40% average across all medication categories).

Timeline: 60 days for standard, 72 hours for expedited.

Step 3: State insurance commissioner complaint (if external review denied) File a complaint with your state insurance department. This doesn't overturn the denial, but it creates a regulatory record. If your state has a coverage mandate and your plan is fully insured, the commissioner may find the denial violated state law.

Reality check: The appeal process takes 60-120 days total. Most patients don't complete it. The highest overturn rates occur when:

• The plan's denial cited missing documentation that you can now provide
• Your BMI or comorbidity profile clearly meets the plan's stated criteria
• Your state has a coverage mandate the plan violated

Appeals rarely succeed when the plan document explicitly excludes weight loss medications. You can't appeal a policy exclusion, only a misapplication of policy.

The compounded alternative for denied claims

When insurance denies coverage or doesn't cover weight loss medications at all, compounded semaglutide and tirzepatide become the primary accessible option.

Pricing comparison:

Option	Monthly cost	Insurance involvement
Brand-name Wegovy (with insurance, covered)	$25-300 copay	Required
Brand-name Wegovy (cash price, no insurance)	$1,200-1,400	None
Compounded semaglutide (FormBlends)	$179-279	None
Compounded semaglutide (other telehealth platforms)	$199-499	None
Compounded tirzepatide (FormBlends)	$279-379	None

When compounded makes sense:

• Your insurance explicitly excludes weight loss medications
• Your prior authorization was denied after appeal
• You're on Medicare (which can't cover weight loss medications)
• Your copay exceeds $300/month
• You want treatment to start this week, not in 30-60 days after PA approval

When brand-name makes sense:

• Your insurance covers it with a copay under $150
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your employer or plan offers manufacturer copay assistance

The clinical outcomes for compounded semaglutide closely track the brand-name version because the active ingredient is identical. The difference is delivery mechanism (vial and syringe vs. pen), FDA approval status (compounded medications are not FDA-approved), and price.

For detailed compounded semaglutide information, see our guide at /articles/cost-and-insurance/compounded-semaglutide-cost-guide/.

FAQ

What insurance plans cover Wegovy? About 60% of commercial insurance plans cover Wegovy for obesity as of 2026, almost always with prior authorization requiring BMI ≥30 or ≥27 with comorbidities. Medicare Part D excludes Wegovy by federal law. Medicaid coverage exists in 12 states.

Does Blue Cross Blue Shield cover weight loss medication? It depends on your specific Blue Cross plan. Fully insured Blue Cross plans cover weight loss medications in about 55% of cases. Self-funded employer plans using Blue Cross as administrator vary from full coverage to complete exclusion based on the employer's benefit design.

Does Medicare cover Ozempic for weight loss? No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes, not for weight loss. The weight loss that occurs during diabetes treatment is considered a side effect, not the primary indication.

Does Medicaid cover Zepbound? Medicaid coverage for Zepbound varies by state. As of 2026, 12 states cover Zepbound for obesity with prior authorization. 31 states exclude weight loss medications entirely. Check your state Medicaid formulary for current status.

What is prior authorization for weight loss medication? Prior authorization is your insurance company's clinical review process before approving coverage. You (through your provider) submit documentation proving you meet the plan's medical criteria. Approval rates for weight loss indications average 42% on first submission.

Why did my insurance deny Wegovy? The most common denial reasons are: BMI below the plan's threshold, missing documentation of prior diet/exercise attempts, off-label prescribing (wrong diagnosis code), plan exclusion of all weight loss medications, or incomplete prior authorization packet.

Can I appeal a weight loss medication denial? Yes. You have the right to internal appeal (reviewed by your insurance company) and external appeal (reviewed by independent physician). The overturn rate is about 30-40% if you submit complete clinical documentation addressing the specific denial reason.

Does insurance cover Ozempic or Wegovy? Insurance coverage differs by medication and indication. Ozempic (approved for diabetes) is covered by about 85% of commercial plans when prescribed for diabetes. Wegovy (approved for weight loss) is covered by about 60% of commercial plans when prescribed for obesity.

What BMI do you need for insurance to cover weight loss medication? Most plans require BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea). Some plans require BMI ≥35 for coverage.

How much does Wegovy cost with insurance? When covered, Wegovy copays range from $25 to $300 per month depending on your formulary tier and deductible status. The Novo Nordisk savings card can reduce copays to $25/month for eligible commercial insurance patients.

Does insurance cover compounded semaglutide? No. Insurance plans do not cover compounded medications. Compounded semaglutide is a cash-pay option for patients whose insurance doesn't cover brand-name weight loss medications or whose copays are unaffordable.

What states require insurance to cover weight loss medication? As of 2026, California, New York, and Massachusetts have laws requiring commercial insurance plans to cover FDA-approved obesity medications. These mandates apply only to fully insured plans, not self-funded employer plans.

How long does prior authorization take for weight loss medication? Standard prior authorization review takes 72 hours to 14 days. If approved, coverage begins immediately. If denied, you can appeal, which adds 30-90 days. The total timeline from prescription to first dose ranges from 1 week to 4 months.

Does UnitedHealthcare cover Mounjaro for weight loss? UnitedHealthcare plans vary. Mounjaro is FDA-approved only for diabetes, not weight loss. When prescribed off-label for weight loss, most UnitedHealthcare plans deny coverage. When prescribed for diabetes, coverage is typical with prior authorization.

Can I use a manufacturer savings card with insurance? Yes, if you have commercial insurance. The Novo Nordisk savings card (for Wegovy and Ozempic) and the Lilly savings card (for Zepbound and Mounjaro) reduce copays for eligible patients. Medicare and Medicaid patients are excluded from manufacturer savings programs by federal law.

Sources

1. International Foundation of Employee Benefit Plans. 2025 Employer-Sponsored Health Benefits Survey. IFEBP. 2025.
2. Avalere Health. Medicare Advantage Supplemental Benefits Analysis: Anti-Obesity Medications. Avalere. 2025.
3. MMIT (Managed Markets Insight & Technology). Prior Authorization Approval Rates for GLP-1 Receptor Agonists. MMIT. 2025.
4. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. CMS. 2024.
5. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Obesity and Obesity Medicine. Endocr Pract. 2024.
6. Kaiser Family Foundation. State Medicaid Coverage of Weight Loss Medications: 50-State Survey. KFF. 2026.
7. National Conference of State Legislatures. State Insurance Mandates for Obesity Treatment. NCSL. 2025.
8. Novo Nordisk. Wegovy Prescribing Information. Novo Nordisk A/S. 2024.
9. Eli Lilly. Zepbound Prescribing Information. Lilly USA. 2024.
10. U.S. Department of Labor. ERISA and State Insurance Regulation: Preemption Analysis. DOL. 2023.
11. American Medical Association. Prior Authorization Reform: Physician Survey Results. AMA. 2025.
12. GoodRx Research. Insurance Coverage Patterns for GLP-1 Medications 2024-2026. GoodRx. 2026.
13. Academy of Managed Care Pharmacy. Formulary Management of Anti-Obesity Medications. AMCP. 2025.
14. Congressional Budget Office. Budgetary Effects of the Treat and Reduce Obesity Act. CBO. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.